Pharmaceutical News

RSS

New compounds can target RNase H enzyme in HIV

Scientists who study HIV are facing a troubling consequence of their own success. They created drugs that can now give infected patients almost normal life expectancy. However, those same drugs will eventually cause the constantly mutating virus to evolve into a form that eludes current treatments.

18 Jan 2013

Carob extract could fight the microbe responsible for listeriosis

The latest episode in the American Chemical Society's (ACS') award-winning Global Challenges/Chemistry Solutions podcast series reports that an antibacterial extract from the leaves of the carob tree (the source of a popular chocolate substitute) could fight the microbe responsible for the serious form of food poisoning called listeriosis.

17 Jan 2013

MPL vaccine can stimulate brain's natural defense mechanisms in people with AD

A team of researchers from Universit- Laval, CHU de Qu-bec, and pharmaceutical firm GlaxoSmithKline (GSK) has discovered a way to stimulate the brain's natural defense mechanisms in people with Alzheimer's disease.

17 Jan 2013

Researchers identify potential sources of medicines derived from plants against diabetes

A group of researchers from the university's School of Science, led by Dr Solomon Habtemariam, believe they have identified potential sources of medicines derived from plants which may have fewer adverse side-effects for diabetes sufferers.

17 Jan 2013

New menu of 61 genetically engineered E. coli strains may improve efficacy of vaccines

Researchers at The University of Texas at Austin have developed a menu of 61 new strains of genetically engineered bacteria that may improve the efficacy of vaccines for diseases such as flu, pertussis, cholera and HPV.

17 Jan 2013

Polypill could reduce CVD and stroke in Latin Americans by up to 21% at lower cost

A single combination pill could reduce cardiovascular disease and stroke in Latin Americans by up to 21 percent at a cost of about $35 per quality adjusted life year gained, according to a study led by a University of Wisconsin School of Medicine and Public Health research team.

17 Jan 2013

Abattis receives Intl Class 5 Trademark for DefenZall in the U.S. and Taiwan

Abattis Bioceuticals Corp., announces it has been granted Intl Class 5 Trademark for DefenZall in Taiwan and the USA.

17 Jan 2013

QrxPharma to resubmit MOXDUO NDA with FDA

QRxPharma Limited announced today that the steps necessary for approval of immediate release MOXDUO have been clarified with the United States Food and Drug Administration (FDA).

17 Jan 2013

Report describes first successful practical synthesis of AMF-26 anti-cancer substance

Scientists are reporting development of the first practical way to make large amounts of a promising new anti-cancer substance that kills cancer cells differently than existing medicines.

17 Jan 2013

UCLA, NanoSmart partner to develop novel cancer drug delivery platform

NanoSmart Pharmaceuticals, a private biotechnology company, has entered into a research collaboration agreement with University of California Los Angeles (UCLA) to continue the development of NanoSmart's novel drug delivery platform for the treatment of cancer and other life-threatening diseases.

17 Jan 2013

Tzamal Medical, Duchesnay partner to distribute and sell Diclectin for management of NVP

Duchesnay Inc. and Tzamal Medical Group Ltd today announced that they have signed an agreement whereby Tzamal Medical Group has been granted exclusive rights to distribute and sell throughout the Israeli market the prescription medicine Diclectin (doxylamine 10 mg/pyridoxine 10 mg delayed-release tablet) indicated for the management of nausea and vomiting of pregnancy (NVP).

17 Jan 2013

Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation-positive NSCLC

Boehringer Ingelheim today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA).

17 Jan 2013

Scientists to investigate how cancer cells hide to avoid chemotherapy drugs

Scientists hope to improve leukaemia treatment by investigating how cancer cells use 'hiding places' in the body to avoid chemotherapy drugs.

17 Jan 2013

Astellas announces FDA acceptance of Tarceva sNDA for EGFR activating mutation-positive NSCLC

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for Tarceva (erlotinib) for first-line use in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) activating mutations.

17 Jan 2013

Protein Sciences receives FDA approval for Flublok vaccine

The U.S. Food and Drug Administration today announced that it has approved Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology. Flublok is approved for the prevention of seasonal influenza in people 18 through 49 years of age.

16 Jan 2013

Tamoxifen can counteract some pathologic features in mouse model of DMD

A new study has found that tamoxifen, a well-known breast cancer drug, can counteract some pathologic features in a mouse model of Duchenne muscular dystrophy (DMD). At present, no treatment is known to produce long-term improvement of the symptoms in boys with DMD, a debilitating muscular disorder that is characterized by progressive muscle wasting, respiratory and cardiac impairments, paralysis, and premature death.

16 Jan 2013

Blocking cholesterol biosynthesis pathway in cancer cells appears to improve ability of common drugs

Shutting down a specific pathway in cancer cells appears to improve the ability of common drugs to wipe those cells out, according to new research from scientists at Fox Chase Cancer Center, published in the January issue of Cancer Discovery.

16 Jan 2013

WHO recommends switching to injectable polio vaccine

"[T]his month the World Health Organization (WHO) in Geneva, Switzerland, proposed a shift in [polio] vaccination strategy from oral vaccines to injected ones that may have to be administered in clinics," Nature reports, adding, "The change is needed to mop up the last remaining pockets of polio, but experts say that it poses challenges in [rural areas], which have poor access to health care."

16 Jan 2013

Thermo Scientific QMS Everolimus Assay Kit receives CE Mark for liver transplant application

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its Thermo Scientific QMS Everolimus Assay Kit has been CE marked for sale in the European Union for a third application, namely liver transplants.

From Thermo Fisher Scientific Inc. 16 Jan 2013

Elan, Biogen Idec submit applications to FDA and EMA for updation of TYSABRI labels

Today Biogen Idec and Elan Corporation, plc announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the TYSABRI (natalizumab) labels.

16 Jan 2013

Pharmaceutical News

New compounds can target RNase H enzyme in HIV

Carob extract could fight the microbe responsible for listeriosis

MPL vaccine can stimulate brain's natural defense mechanisms in people with AD

Researchers identify potential sources of medicines derived from plants against diabetes

New menu of 61 genetically engineered E. coli strains may improve efficacy of vaccines

Polypill could reduce CVD and stroke in Latin Americans by up to 21% at lower cost

Abattis receives Intl Class 5 Trademark for DefenZall in the U.S. and Taiwan

QrxPharma to resubmit MOXDUO NDA with FDA

Report describes first successful practical synthesis of AMF-26 anti-cancer substance

UCLA, NanoSmart partner to develop novel cancer drug delivery platform

Tzamal Medical, Duchesnay partner to distribute and sell Diclectin for management of NVP

Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation-positive NSCLC

Scientists to investigate how cancer cells hide to avoid chemotherapy drugs

Astellas announces FDA acceptance of Tarceva sNDA for EGFR activating mutation-positive NSCLC

Protein Sciences receives FDA approval for Flublok vaccine

Tamoxifen can counteract some pathologic features in mouse model of DMD

Blocking cholesterol biosynthesis pathway in cancer cells appears to improve ability of common drugs

WHO recommends switching to injectable polio vaccine

Thermo Scientific QMS Everolimus Assay Kit receives CE Mark for liver transplant application

Elan, Biogen Idec submit applications to FDA and EMA for updation of TYSABRI labels

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News